Allmang C, Hussar P, Duritis I, Popovska-Percinic F
Curr Issues Mol Biol. 2024; 46(12):14259-14269.
PMID: 39727982
PMC: 11674384.
DOI: 10.3390/cimb46120854.
Saleem M, Zubair M, Abbas S, Hojeij M
Ann Med Surg (Lond). 2024; 86(11):6399-6403.
PMID: 39525721
PMC: 11543222.
DOI: 10.1097/MS9.0000000000002624.
Bomholt A, Johansen C, Galsgaard K, Elmelund E, Winther-Sorensen M, Holst J
Am J Physiol Renal Physiol. 2024; 327(5):F712-F724.
PMID: 39265079
PMC: 11563637.
DOI: 10.1152/ajprenal.00088.2024.
Daida T, Shin B, Cepeda C, Devaskar S
Nutrients. 2024; 16(14).
PMID: 39064806
PMC: 11279700.
DOI: 10.3390/nu16142363.
Kanbay M, Copur S, Guldan M, Ozbek L, Hatipoglu A, Covic A
Clin Kidney J. 2024; 17(7):sfae195.
PMID: 39050867
PMC: 11267238.
DOI: 10.1093/ckj/sfae195.
Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.
Xu B, Li S, Kang B, Fan S, Chen C, Li W
Mol Biol Rep. 2023; 50(11):9637-9647.
PMID: 37819499
DOI: 10.1007/s11033-023-08836-0.
The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy.
Xu H, Fu J, Tu Q, Shuai Q, Chen Y, Wu F
J Physiol Biochem. 2023; 80(1):27-39.
PMID: 37792168
DOI: 10.1007/s13105-023-00974-0.
(Zebra)fishing for nephrogenesis genes.
Chambers B, Weaver N, Lara C, Nguyen T, Wingert R
Tissue Barriers. 2023; 12(2):2219605.
PMID: 37254823
PMC: 11042071.
DOI: 10.1080/21688370.2023.2219605.
Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice.
Erdem S, Titus A, Patel D, Patel N, Sattar Y, Glazier J
Cureus. 2023; 15(4):e37310.
PMID: 37182087
PMC: 10166724.
DOI: 10.7759/cureus.37310.
Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans.
Kim M, Song Y, Choi J, Ji H, Yang E, Park J
Pharmaceutics. 2023; 15(3).
PMID: 36986803
PMC: 10058973.
DOI: 10.3390/pharmaceutics15030942.
SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives.
Dutka M, Bobinski R, Francuz T, Garczorz W, Zimmer K, Ilczak T
Cancers (Basel). 2022; 14(23).
PMID: 36497303
PMC: 9738342.
DOI: 10.3390/cancers14235811.
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice.
Skrabic R, Kumric M, Vrdoljak J, Rusic D, Skrabic I, Vilovic M
Biomedicines. 2022; 10(10).
PMID: 36289720
PMC: 9598622.
DOI: 10.3390/biomedicines10102458.
Carbohydrate-based drugs launched during 20002021.
Cao X, Du X, Jiao H, An Q, Chen R, Fang P
Acta Pharm Sin B. 2022; 12(10):3783-3821.
PMID: 36213536
PMC: 9532563.
DOI: 10.1016/j.apsb.2022.05.020.
Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease.
Nakano D, Akiba J, Tsutsumi T, Kawaguchi M, Yoshida T, Koga H
Med Mol Morphol. 2022; 55(4):304-315.
PMID: 36131166
PMC: 9606064.
DOI: 10.1007/s00795-022-00334-9.
Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects.
Takashima M, Nakamura K, Kiyohara T, Wakisaka Y, Hidaka M, Takaki H
Commun Biol. 2022; 5(1):653.
PMID: 35780235
PMC: 9250510.
DOI: 10.1038/s42003-022-03605-4.
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.
Feijoo-Bandin S, Aragon-Herrera A, Otero-Santiago M, Anido-Varela L, Morana-Fernandez S, Tarazon E
Int J Mol Sci. 2022; 23(10).
PMID: 35628443
PMC: 9144929.
DOI: 10.3390/ijms23105634.
SGLT inhibitors as antidiabetic agents: a comprehensive review.
Kshirsagar R, Kulkarni A, Chouthe R, Pathan S, Une H, Reddy G
RSC Adv. 2022; 10(3):1733-1756.
PMID: 35494673
PMC: 9048284.
DOI: 10.1039/c9ra08706k.
Glucose transporters as markers of diagnosis and prognosis in cancer diseases.
Szablewski L
Oncol Rev. 2022; 16(1):561.
PMID: 35340885
PMC: 8941341.
DOI: 10.4081/oncol.2022.561.
Angiotensin II and AT Receptors in the Proximal Tubules of the Kidney: New Roles in Blood Pressure Control and Hypertension.
Leite A, Li X, Nwia S, Hassan R, Zhuo J
Int J Mol Sci. 2022; 23(5).
PMID: 35269547
PMC: 8910592.
DOI: 10.3390/ijms23052402.
Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches.
Xu J, Hirai T, Koya D, Kitada M
J Clin Med. 2022; 11(1).
PMID: 35011882
PMC: 8745121.
DOI: 10.3390/jcm11010137.